ISB News

Dr. Wei Wei Awarded CARE Grant

The Andy Hill Cancer Research Endowment (CARE) announced ISB Assistant Professor Dr. Wei Wei as a CARE Fund Distinguished Researcher and awarded him $500,000.

“I am extremely honored. This is an unforgettable moment that is much bigger than me — it would not have been possible without the support of my team members, my colleagues, and my institution,” said Wei. “The award recognizes successes of the past and the promise of the future. With the generous support of the CARE fund, I will do everything I can to fight cancer.”

The Wei Lab is developing micro technologies that cultivate new understandings in fundamental cancer biology, as well as new opportunities in translational research in the clinic.

Wei is the second ISB researcher to receive grant funding distinguished researcher funding from The Andy Hill CARE Fund, a public-private partnership that supports cancer research in Washington state. ISB President Dr. Jim Heath was awarded $500,000 in December 2017.

Wei joined ISB in August. Prior to coming to Seattle, he earned his PhD from Caltech and served as a faculty member at UCLA Medical School.

Read a recent Q&A with Wei that delves into his research career, how research might change over the next decade, and his interests and hobbies when not focusing on science.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.